Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Phillip J MeasePhilip S HelliwellPaula Silwinska-StanczykMalgorzata MiakiszAndrew OstorElena PeevaMichael S VincentQiankun SunVanja SikiricaRandall WinnetteRuolun QiuGang LiGang FengJean S BeebeDavid A MartinPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Brepocitinib 30 and 60 mg QD were superior to placebo at reducing signs and symptoms of PsA. Brepocitinib was generally well tolerated throughout the 52-week study with a safety profile consistent with other brepocitinib clinical trials.